High expression of PI3K core complex genes is associated with poor prognosis in chronic lymphocytic leukemia

Leukemia Research

Volumn 39, Issue 6, 2015, Pages 555-560

  Kristensen, Louise ^a   Kristensen, Thomas ^a   Abildgaard, Niels ^a   Thomassen, Mads ^a   Frederiksen, Mikael ^b   Mourits Andersen, Torben ^c   Møller, Michael Boe ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b Haderslev Hospital   (Denmark)

^c ESBJERG HOSPITAL   (Denmark)

Author keywords

Autophagy; BECN1; Chronic lymphocytic leukemia; PIK3C3; PIK3R4; Prognosis

Indexed keywords

BECLIN 1; BENDAMUSTINE; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; PREDNISONE; PROTEIN KINASE ZAP 70; RITUXIMAB; VINCRISTINE; APOPTOSIS REGULATORY PROTEIN; BECN1 PROTEIN, HUMAN; MEMBRANE PROTEIN; PIK3R4 PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE VPS15;

ADULT; AGED; ARTICLE; BECLIN 1 GENE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CHROMOSOME 11Q; CHROMOSOME 17P; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DENMARK; FEMALE; GENE; GENE EXPRESSION; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; IMMUNOGLOBULIN HEAVY CHAIN GENE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PIK3C3 GENE; PIK3R4 GENE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TIME TO TREATMENT; TRISOMY 12; BIOSYNTHESIS; DISEASE FREE SURVIVAL; ENZYMOLOGY; GENE EXPRESSION REGULATION; MIDDLE AGED; MORTALITY; SURVIVAL RATE;

AGED; APOPTOSIS REGULATORY PROTEINS; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MEMBRANE PROTEINS; MIDDLE AGED; SURVIVAL RATE; VACUOLAR SORTING PROTEIN VPS15;

EID: 84929517706     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2015.02.008     Document Type: Article

References (38)

1. Hallek M., et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008, 111(12):5446-5456.
2. Shanafelt T.D., Geyer S.M., Kay N.E. Prognosis at diagnosis: integrating molecular biologic insights into clinical practice for patients with CLL. Blood 2004, 103(4):1202-1210.
3. Ghia P., Ferreri A.M., Caligaris-Cappio F. Chronic lymphocytic leukemia. Crit Rev Oncol Hematol 2007, 64(3):234-246.
4. Inamdar K.V., Bueso-Ramos C.E. Pathology of chronic lymphocytic leukemia: an update. Ann Diagn Pathol 2007, 11(5):363-389.
5. Jean S., Kiger A.A. Classes of phosphoinositide 3-kinases at a glance. J Cell Sci 2014, 127(Pt. 5):923-928.
6. Wong K.K., Engelman J.A., Cantley L.C. Targeting the PI3K signaling pathway in cancer. Curr Opin Genet Dev 2010, 20(1):87-90.
7. Furman R.R., et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med 2014, 370(11):997-1007.
8. Jin S., White E. Role of autophagy in cancer: management of metabolic stress. Autophagy 2007, 3(1):28-31.
9. White E., DiPaola R.S. The double-edged sword of autophagy modulation in cancer. Clin Cancer Res 2009, 15(17):5308-5316.
10. Lum J.J., et al. Growth factor regulation of autophagy and cell survival in the absence of apoptosis. Cell 2005, 120(2):237-248.
11. Qu X., et al. Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene. J Clin Invest 2003, 112(12):1809-1820.
12. Chen Y., Klionsky D.J. The regulation of autophagy-unanswered questions. J Cell Sci 2011, 124(Pt. 2):161-170.
13. Kihara A., et al. Beclin-phosphatidylinositol 3-kinase complex functions at the trans-Golgi network. EMBO Rep 2001, 2(4):330-335.
14. Petiot A., et al. Distinct classes of phosphatidylinositol 3'-kinases are involved in signaling pathways that control macroautophagy in HT-29 cells. J Biol Chem 2000, 275(2):992-998.
15. Ekiz H.A., Can G., Baran Y. Role of autophagy in the progression and suppression of leukemias. Crit Rev Oncol Hematol 2012, 81(3):275-285.
16. Zoppoli G., et al. Potent synergistic interaction between the Nampt inhibitor APO866 and the apoptosis activator TRAIL in human leukemia cells. Exp Hematol 2010, 38(11):979-988.
17. Laane E., et al. Cell death induced by dexamethasone in lymphoid leukemia is mediated through initiation of autophagy. Cell Death Differ 2009, 16(7):1018-1029.
18. Sharma A., et al. BECN1 and BIM interactions with MCL-1 determine fludarabine resistance in leukemic B cells. Cell Death Dis 2013, 4:e628.
19. Mahoney E., et al. ER stress and autophagy: new discoveries in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol. Blood 2012, 120(6):1262-1273.
20. El-Khoury V., et al. Disruption of autophagy by the histone deacetylase inhibitor MGCD0103 and its therapeutic implication in B-cell chronic lymphocytic leukemia. Leukemia 2014.
21. MacCallum S.F., et al. Dysregulation of autophagy in chronic lymphocytic leukemia with the small-molecule Sirtuin inhibitor Tenovin-6. Sci Rep 2013, 3:1275.
22. Green T.M., de Stricker K., Moller M.B. Validation of putative reference genes for normalization of Q-RT-PCR data from paraffin-embedded lymphoid tissue. Diagn Mol Pathol 2009, 18(4):243-249.
23. Ghia P., et al. ERIC recommendations on IGHV gene mutational status analysis in chronic lymphocytic leukemia. Leukemia 2007, 21(1):1-3.
24. Rassenti L.Z., et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med 2004, 351(9):893-901.
25. Malignt lymfom National Årsrapport 2012. 2012; Available from: http://lymphoma.dk/download.php?cdfda5e52002d0a0021ee4cd94d1bcc1&target=1.
26. Tjonnfjord G.E., et al. Chronic lymphocytic leukaemia in Norway-incidence and prognostic markers at diagnosis. Tidsskr Nor Laegeforen 2012, 132(18):2056-2059.
27. Miracco C., et al. Protein and mRNA expression of autophagy gene Beclin 1 in human brain tumours. Int J Oncol 2007, 30(2):429-436.
28. Ding Z.B., et al. Association of autophagy defect with a malignant phenotype and poor prognosis of hepatocellular carcinoma. Cancer Res 2008, 68(22):9167-9175.
29. Wirawan E., et al. Beclin1: a role in membrane dynamics and beyond. Autophagy 2012, 8(1):6-17.
30. Ahn C.H., et al. Expression of beclin-1: an autophagy-related protein, in gastric and colorectal cancers. APMIS 2007, 115(12):1344-1349.
31. Vinod V., et al. 'How can I halt thee?' The puzzles involved in autophagic inhibition. Pharmacol Res 2014, 82:1-8.
32. Foster J.G., et al. Inhibition of PI3K signaling spurs new therapeutic opportunities in inflammatory/autoimmune diseases and hematological malignancies. Pharmacol Rev 2012, 64(4):1027-1054.
33. Wirawan E., et al. Caspase-mediated cleavage of Beclin-1 inactivates Beclin-1-induced autophagy and enhances apoptosis by promoting the release of proapoptotic factors from mitochondria. Cell Death Dis 2010, 1:e18.
34. Packham G., Stevenson F.K. Bodyguards and assassins. Bcl-2 family proteins and apoptosis control in chronic lymphocytic leukaemia. Immunology 2005, 114(4):441-449.
35. Wu Y.T., et al. Dual role of 3-methyladenine in modulation of autophagy via different temporal patterns of inhibition on class I and III phosphoinositide 3-kinase. J Biol Chem 2010, 285(14):10850-10861.
36. Abrahamsen H., Stenmark H., Platta H.W. Ubiquitination and phosphorylation of Beclin 1 and its binding partners: tuning class III phosphatidylinositol 3-kinase activity and tumor suppression. FEBS Lett 2012, 586(11):1584-1591.
37. Wu P., Liu T., Hu Y. PI3K inhibitors for cancer therapy: what has been achieved so far?. Curr Med Chem 2009, 16(8):916-930.
38. Vadas O., et al. Structural basis for activation and inhibition of class I phosphoinositide 3-kinases. Sci Signal 2011, 4(195):re2.